Tilray Medical, a global leader in medical cannabis research, cultivation, production, products and distribution and a division of Tilray Brands, Inc. ("Tilray") (NASDAQ:TLRY, TSX:TLRY), today announced a key regulatory milestone in Europe: INFARMED, Portugal’s National Authority of Medicines and Health Products, has approved the quality control laboratory at Tilray Medical’s EU-GMP-certified facility in Cantanhede, Portugal, to conduct microbiological and chemical/physical testing in-house. The approval gives Tilray Medical greater command over critical quality testing, accelerates product release capabilities, and strengthens its Portugal facility as a strategic launchpad for pharmaceutical-grade medical cannabis supply across regulated international markets.

With this authorization, Tilray Medical further differentiates its European production platform by embedding advanced testing capabilities directly within its EU-GMP infrastructure. The approval reinforces Cantanhede as a strategic center for cultivation, production, testing, and international supply, and comes as demand for trusted, pharmaceutical-grade medical cannabis continues to grow across regulated markets.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.